Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

NCT00425204

Colorectal Cancer Non-Small Cell Lung Cancer Prostate Cancer +2 more

COMPLETED PHASE2

A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00756444

Squamous Cell Carcinoma of Head and Neck

COMPLETED PHASE2

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

NCT02179918

Advanced Solid Tumors

COMPLETED PHASE1

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

NCT07053904

Advanced Solid Tumors

ENROLLING_BY_INVITATION PHASE1

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531

Advanced Solid Tumors (Part A/B/C/D) Non-small Cell Lung Cancer (Part E) Melanoma (Part E) +5 more

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors Oncology Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug

Group Type EXPERIMENTAL

panitumumab (ABX-EGF)

Intervention Type DRUG

6 mg/kg once every 2 weeks

Cohort 2

Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.

Group Type EXPERIMENTAL

Panitumumab

Intervention Type DRUG

9 mg/kg once every 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

panitumumab (ABX-EGF)

6 mg/kg once every 2 weeks

Intervention Type DRUG

Panitumumab

9 mg/kg once every 3 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologic diagnosis of advanced solid tumors that are refractory to at least 1 standard therapy or for which no standard therapy is available and have not received more than 3 prior treatment regimens (not inclusive of hormonal therapies for breast and prostate cancer subjects) for the advanced solid tumor (tumor must be diagnosed by standard criteria for the specific tumor type)
* Measurable disease or evaluable (non-measurable) disease per RECIST guidelines (all sites of disease must be evaluated within 28 days before enrollment)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Life expectancy of \> 3 months as documented by the investigator
* If history of other primary cancer, subject will be eligible only if she or he has:

* Non-melanomatous skin cancer, not requiring treatment
* Curatively treated cervical carcinoma in situ
* Other primary solid tumor curatively treated with no known active disease present for the last 5 years and no treatment administered for the last 3 years
* Man or woman 18 years of age or older
* Paraffin-embedded tumor tissue (from primary or metastatic tumor tissue) available for immunohistochemistry studies of EGFr expression (biopsy or archived tissue are acceptable). The immunohistochemical EGFr staining and evaluation must be conducted at the designated central laboratory using the DakoCytomation EGFR pharmDXTM kit. Local laboratory EGFr expression is not permitted for the purpose of eligibility in this study
* Hematologic function, as follows:

* Absolute neutrophil count (ANC) \> 1.5 x 109/L
* Platelet count \> 100 x 109/L
* Hemoglobin \> 8 g/dL
* Renal function, as follows:

o Creatinine \< 2.0 mg/dL
* Hepatic function, as follows:

* Aspartate aminotransferase (AST) \< 3 x ULN (if liver metastases ≤ 5 x ULN)
* Alanine aminotransferase (ALT) \< 3 x ULN (if liver metastases ≤ 5 x ULN)
* Bilirubin \< 2 x ULN
* Competent to comprehend, sign, and date an IEC/IRB-approved informed consent form

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No